Systematic review evaluates the interventional effects of astragaloside IV on myocardial fibrosis, indicating benefits in cardiac function and structure.
Key Points
AS-IV significantly reduced morphostructural indices of myocardial fibrosis, improving overall cardiac function.
In a meta-analysis of 38 studies, AS-IV improved left ventricular ejection fraction and decreased inflammatory markers.
Methodologically, the analysis assessed risk of bias and performed subgroup analyses based on species and dosage.
These findings highlight AS-IV's potential as a supportive treatment for myocardial fibrosis, though effects on certain cardiac dimensions were not significant.